Lundbeck competitors

• Pharmaceutical/Biotech executive with over 23 years’ experience in successful commercialization (sales, marketing, trade, managed markets, training and development, market research, sales operations, supply chain), general operations (IT, facilities), business development, leadership development, investor relations and strategic planning. • Proven track record of commercialization success in diverse business structures including large public pharma, start-up specialty private pharma and public biotech inclusive of building and scaling commercial operations to the needs of the organization. • Accomplishments include launching a blockbuster mass market brand/category, re-launching specialty and mass market brands to generate positive brand P&Ls, and corporate M&A leading to the exit of a specialty pharma company for $1.65B.

Mihael H. Polymeropoulos, M.D. co-founded Vanda and has served as President, Chief Executive Officer and a Director since May 2003. Prior to joining Vanda, Dr. Polymeropoulos was Vice President and Head of the Pharmacogenetics Department at Novartis AG from 1998 to 2003. Prior to his tenure at Novartis, he served as Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, National Human Genome Research Institute, from 1992 to 1998.

Kalyanasundaram Kal Sundaram Subramanian is a Chief Executive Officer at TARO PHARMACEUTICAL INDUSTRIES LTD. and is based in 1407 Broadway Suite 318, New York City, New York.